Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Abbott India Ltd gains for fifth session
Abbott India Ltd is quoting at Rs 26830, up 3.61% on the day as on 12:44 IST on the NSE. The stock is down 22.2% in last one year as compared to a 3.99% gain in NIFTY and a 15.09% gain in the Nifty Pharma.
Abbott India Ltd drops for fifth straight session
Abbott India Ltd is quoting at Rs 26020, down 1.03% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.
Abbott India clocks PAT of Rs 394.93 crore in March'26 quarter
Abbott India has reported 7.6% increase in consolidated net profit to Rs 394.93 crore on a 6.5% rise in revenue to Rs 1,709.51 crore in Q4 FY26 as compared with Q4 FY25.
Abbott India standalone net profit rises 7.60% in the March 2026 quarter
Sales rise 6.54% to Rs 1709.51 crore
₹656 Dividend Bonanza: 71,000 retail shareholders of this MNC drugmaker set for their highest payout
This is the highest dividend payout on record for Abbott India, having surpassed the ₹475 per share it had paid shareholders last year.
Abbott Laboratories stock hits 52-week low at $86.15 By Investing.com - Investing.com India
Abbott Laboratories stock hits 52-week low at $86.15 By Investing.comInvesting.com India
JPMorgan downgrades this drugmaker, cuts price target by 19% citing growth challenges
Of the eight analysts who have coverage on the Abbott India stock, six have a 'buy' rating, while one each have 'hold' and 'sell' ratings.
Market Trading Guide: Buy Balrampur Chini and Abbott India on Thursday for gains up to 5%
The Nifty fell 1.6% amid broad-based selling triggered by the Iran-Israel conflict, with financials, auto and energy stocks leading losses. Analysts flag weak momentum and advise a sell-on-rise approach, while recommending Balrampur Chini Mills and Abbott India for short-term gains.
Market Trading Guide: Buy Balrampur Chini and Abbott India on Thursday for gains up to 5% - The Economic Times
Market Trading Guide: Buy Balrampur Chini and Abbott India on Thursday for gains up to 5%The Economic Times
Abbott signs pact with Novo Nordisk to offer semaglutide
Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.
Abbott India to sell Novo Nordisk’s semaglutide, weight-loss drug behind Ozempic
Abbott India has partnered Novo Nordisk to market semaglutide under the Extensior brand, aiming to tap rising demand for advanced diabetes therapies in one of the world’s fastest-growing markets.
What sets apart MNC pharma companies from their Indian counterparts
Dividend payments by Abbott and Pfizer increased significantly in last two fiscal years even as they lag Indian majors in growth